Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by prophetoffactzon May 11, 2023 3:07pm
361 Views
Post# 35443842

Zacks on PLX:

Zacks on PLX:

We expect milestones to be due upon approval from partner Chiesi; however, these amounts have not been disclosed.

 

We update our valuation to reflect the approval of Elfabrio, increasing our probability of success to 100%. Along with sharecount modifications, this generates a price target of $16.00 per share, a greater than 5x upside from the latest closing price.

We are looking forward to an investor day in June that will identify the pathway forward for development candidates and we hope provide an early look at Chiesi’s early commercialization efforts. We are interested to see how the relationship with Chiesi will evolve and how new in-development candidates PRX-115 and PRX-119 will advance.

<< Previous
Bullboard Posts
Next >>